Reference health
Identification of an Immune Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of  Urothelial Cancer
35/35 checkable references clean · checked 2026-09-09
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 35 checked references that resolve
resolves10.1200/JCO.2010.32.3139
International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
resolves10.1158/1078-0432.CCR-16-0066
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
resolves10.1038/nature13904
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
resolves10.1038/s41591-019-0645-6
Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer
resolves10.1016/j.lungcan.2020.07.028
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients
resolves10.1007/s12026-014-8516-1
ImmPort: disseminating data to the public for the future of immunology
resolves10.1093/nar/gks1147
InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation
resolves10.1038/nature25501
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
resolves10.7150/thno.46176
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
resolves10.1073/pnas.0506580102
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
resolves10.1073/pnas.1521416112
Preserving neuroplasticity: Role of glucocorticoids and neurotrophins via phosphorylation
resolves10.1186/s13059-014-0550-8
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
resolves10.1002/sim.6927
Empirical extensions of the lasso penalty to reduce the false discovery rate in high‐dimensional Cox regression models
resolves10.1126/science.aar3593
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
resolves10.1001/jamaoncol.2017.1609
Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer
resolves10.1002/cam4.1905
Construction of immune‐related risk signature for renal papillary cell carcinoma
resolves10.21203/rs.3.rs-35127/v1
A robust eleven-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts
resolves10.21037/tlcr.2018.09.23
Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy
resolves10.1158/1078-0432.ccr-15-1507
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
resolves10.1038/s41573-018-0007-y
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
resolves10.1136/jitc-2019-000169
Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer
resolves10.1158/2326-6066.cir-19-0934
Infiltration by IL22-Producing T Cells Promotes Neutrophil Recruitment and Predicts Favorable Clinical Outcome in Human Colorectal Cancer
resolves10.1016/j.intimp.2019.106019
Th9 cells are subjected to PD-1/PD-L1-mediated inhibition and are capable of promoting CD8 T cell expansion through IL-9R in colorectal cancer
resolves10.1111/imm.12770
T‐cell regulation through a basic suppressive mechanism targeting low‐density lipoprotein receptor‐related protein 1
resolves10.18632/oncotarget.15403
Signal-transducing adaptor protein-2 promotes generation of functional long-term memory CD8+ T cells by preventing terminal effector differentiation
resolves10.1073/pnas.0803386105
Semaphorin 6D regulates the late phase of CD4
<sup>+</sup>
T cell primary immune responses
The 3 references without a DOI — listed, not checked
no DOI — not checkedref24
no DOI — not checkedref25
no DOI — not checkedref28
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-09-09 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2139/ssrn.3745192"><img src="https://citestamp.com/citestamped/10.2139/ssrn.3745192/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2139/ssrn.3745192)